On February 10, 2017 and March 10, 2017, BioSig Technologies, Inc. (the “Company”) consummated a fifth and sixth closing, respectively under the Unit Purchase Agreement, dated October 28, 2016, by and among the Company and certain accredited investors (the “Purchase Agreement”), to which the Company issued to certain additional accredited investors (the “February/March Investors”) an aggregate of 995,571 units (the “Units”), in exchange for aggregate consideration of $1,493,353. Each Unit consists of one share (the “Investor Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and a warrant to purchase one half of one share of Common Stock, exercisable at a price of $1.50 per share (the “Investor Warrants”), at a per Unit price of $1.50. In addition, in connection with the fifth and sixth closings, each February/March Investor became party to that certain Registration Rights Agreement, dated as of October 28, 2016 (the “Registration Rights Agreement”).

As previously reported in the Company’s Current Reports on Form 8-K filed with the Securities and Exchange Commission on November 3, 2016 and December 22, 2016 the Company: (i) consummated the first closing under the Purchase Agreement on October 28, 2016, to which the Company issued to the initial investors (the “Initial Investors”) an aggregate of 346,567 Units in exchange for aggregate consideration of $519,850; (ii) consummated the second closing on November 23, 2016 to which the Company issued to certain additional investors (the “November Investors”) 100,002 Units in exchange for approximately $150,000; (iii) consummated the third and fourth closings on December 16, 2016 and December 22, 2016, respectively, to which the Company issued to certain additional accredited investors (the “December Investors” and collectively with the February/March Investors, the Initial Investors and the November Investors, the “Investors”) an aggregate of 1,143,334 Units, in exchange for aggregate consideration of approximately $1,715,000. The Common Stock issuances on March 10, 2017, resulted in an increase in the number of shares of Common Stock outstanding by more than 5% since the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on December 22, 2016.

The shares of Common Stock and Investor Warrants issued and sold to the Investors were not registered under the Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any state, and were offered and sold in reliance on the exemption from registration under the Securities Act, provided by Section 4(a)(2) and Regulation D (Rule 506) under the Securities Act. Each Investor represented that it was an accredited investor (as defined by Rule 501 under the Securities Act).

About BioSig Technologies, Inc. (OTCMKTS:BSGM)

BioSig Technologies, Inc. is a development-stage medical device company. The Company is developing a technology platform to manage noise and artifacts from cardiac recordings during electrophysiology studies and ablation. It is engaged in developing the Precise Uninterrupted Real-time evaluation of Electrograms (PURE) electro-pneumatic (EP) System. PURE EP System is a surface electrocardiogram and intracardiac multichannel recording and analysis system that acquires, processes and displays electrocardiogram and electrograms required during electrophysiology studies and ablation procedures. The Company’s PURE EP System is designed to assist electrophysiologists with real-time evaluations of electrocardiograms and electrograms, and helps in making clinical decisions in real-time. It is also developing signal-processing tools, which will assist electrophysiologists in differentiating true signals from noise and provide guidance in identifying ablation targets within the PURE EP System.

BioSig Technologies, Inc. (OTCMKTS:BSGM) Recent Trading Information

BioSig Technologies, Inc. (OTCMKTS:BSGM) closed its last trading session up +0.01 at 1.38 with 51,831 shares trading hands.